Rooted in academic excellence, Epistem's inflammation team has developed an extensive knowledge of the field and applied this experience to a portfolio of pre-clinical models. The team has been routinely performing in vitro and in vivo studies for the drug discovery industry for over 10 years. This comprehensive understanding of the models and assays offered enables Epistem to offer a consultative approach to study design; advice can be provided on selection of the most suitable model, particularly with reference to the performance of therapeutic agents. Epistem offers a range of in vivo disease models reflecting several key areas of autoimmune disease. Supported by a suite of mechanistic assays, these can provide a valuable and comprehensive data package.

Epistem continues to develop innovative and clinically relevant assays and models to support the drug discovery and development pipeline. Most recently a validated, in vitro model of psoriasis, addressing the need for a clinically relevant model within the industry, was added to the portfolio.


As a result of Epistem's inflammatory and skin expertise, prestigious funding has been awarded to Epistem in collaboration with ScandiDerma to develop a novel inflammatory human living skin equivalent model. The grant, provided by the UK's Technology Strategy Board and Innovation Norway, recognises global leaders in innovation. The collaboration aims to address the shortage of robust human skin models for testing inflammatory responses.

The Technology Strategy Board is the UK's innovation agency sponsored by the Department for Business, Innovation and Skills and aims to accelerate the development of innovative products and services to meet market needs.

Innovation Norway is the Norwegian Government's most important instrument for innovation supporting companies in developing a competitive advantage and to enhance innovation.